Standard BioTools Total Current Liabilities

Standard BioTools (LAB) currently reports a total current liabilities of $57M as of June 2026. That compares with $98M in the prior-year period — down 42.1% year over year. Use the charts on this page to explore Standard BioTools's total current liabilities history and peer comparisons.

Standard BioTools's total current liabilities decreased from $98M to $57M — a 42.1% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Standard BioTools reported $57M in total current liabilities as of June 2026. That compares with $98M in the prior-year period — down 42.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $57M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Standard BioTools, and consider following LAB for alerts when major investors trade the stock.

Standard BioTools is classified in the Healthcare sector. On total current liabilities, it currently shows $57M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LAB with unrelated industries.